MX2020011960A - Nuevo compuesto que presenta actividad inhibidora de enteropeptidasa. - Google Patents
Nuevo compuesto que presenta actividad inhibidora de enteropeptidasa.Info
- Publication number
- MX2020011960A MX2020011960A MX2020011960A MX2020011960A MX2020011960A MX 2020011960 A MX2020011960 A MX 2020011960A MX 2020011960 A MX2020011960 A MX 2020011960A MX 2020011960 A MX2020011960 A MX 2020011960A MX 2020011960 A MX2020011960 A MX 2020011960A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitory activity
- compound
- novel compound
- enteropeptidase inhibitory
- metabolic diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 102100029727 Enteropeptidase Human genes 0.000 title abstract 3
- 108010013369 Enteropeptidase Proteins 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 230000001747 exhibiting effect Effects 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 3
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003925 fat Substances 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000001162 steatorrhea Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto novedoso que muestra actividad de inhibición de enteropeptidasa, a una sal farmacéuticamente aceptable del mismo, a una composición farmacéutica para prevenir y tratar enfermedades metabólicas tales como obesidad, diabetes mellitus o hiperlipidemia, etc. que comprende el compuesto o una sal farmacéuticamente aceptable, y a un método para prevenir o tratar una enfermedad metabólica usando el compuesto novedoso anterior. El compuesto de la presente invención tiene una excelente actividad inhibidora frente a enteropeptidasa y, por tanto, no se absorbe en el organismo, sino que se excreta al exterior del organismo. Sin embargo, dado que se expulsan juntas no sólo grasas sino también proteínas, tiene pocos efectos secundarios tales como esteatorrea y actúa sólo en el tracto gastrointestinal, de modo que tiene pocos efectos secundarios tales como depresión, y es muy útil como fármaco terapéutico o profiláctico para diversas enfermedades metabólicas tales como obesidad, diabetes mellitus e hiperlipidemia.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180053316 | 2018-05-09 | ||
| KR20180053315 | 2018-05-09 | ||
| PCT/KR2019/005997 WO2019216742A1 (ko) | 2018-05-09 | 2019-05-08 | 엔테로펩디아제 억제 활성을 나타내는 신규 화합물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011960A true MX2020011960A (es) | 2021-01-15 |
Family
ID=68468129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011960A MX2020011960A (es) | 2018-05-09 | 2019-05-08 | Nuevo compuesto que presenta actividad inhibidora de enteropeptidasa. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11447480B2 (es) |
| EP (1) | EP3778577B1 (es) |
| JP (1) | JP7199774B2 (es) |
| KR (1) | KR102325422B1 (es) |
| CN (1) | CN112105604B (es) |
| AU (1) | AU2019265268C1 (es) |
| BR (1) | BR112020022790A2 (es) |
| CA (1) | CA3099268C (es) |
| CL (1) | CL2020002887A1 (es) |
| CO (1) | CO2020014186A2 (es) |
| DK (1) | DK3778577T3 (es) |
| IL (1) | IL278435B2 (es) |
| JO (1) | JOP20200282A1 (es) |
| MX (1) | MX2020011960A (es) |
| PE (1) | PE20211496A1 (es) |
| PH (1) | PH12020551900A1 (es) |
| RU (1) | RU2768755C1 (es) |
| SG (1) | SG11202011083PA (es) |
| UA (1) | UA126099C2 (es) |
| WO (1) | WO2019216742A1 (es) |
| ZA (1) | ZA202007260B (es) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9201956D0 (sv) * | 1992-06-25 | 1992-06-25 | Kabi Pharmacia Ab | Novel nicotinicacid esters |
| DE10228132A1 (de) * | 2002-06-24 | 2004-01-22 | Arzneimittelwerk Dresden Gmbh | Amide cyclischer Aminosäuren als PDE 4 Inhibitoren |
| EP1587800A1 (en) | 2003-01-27 | 2005-10-26 | Astellas Pharma Inc. | Thiazole derivatives and their use as vap-1 inhibitors |
| EP1594854B1 (en) | 2003-02-06 | 2010-09-01 | Bristol-Myers Squibb Company | Thiazolyl-based compounds useful as kinase inhibitors |
| EP2316827B1 (en) * | 2003-07-30 | 2016-01-27 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
| RU2368602C2 (ru) * | 2005-01-26 | 2009-09-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
| WO2008124393A1 (en) | 2007-04-04 | 2008-10-16 | Irm Llc | Benzothiazole derivatives and their use as protein kinase inhibitors |
| WO2009054468A1 (ja) * | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | アゾールカルボキサミド化合物又はその塩 |
| CN102089303A (zh) * | 2008-07-17 | 2011-06-08 | 旭化成制药株式会社 | 含氮杂环化合物 |
| WO2011071048A1 (ja) | 2009-12-07 | 2011-06-16 | 味の素株式会社 | ヘテロアリールカルボン酸エステル誘導体 |
| ES2618024T3 (es) * | 2011-06-07 | 2017-06-20 | Ea Pharma Co., Ltd. | Derivado de éster de ácido carboxílico heterocíclico |
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9346776B2 (en) * | 2014-02-13 | 2016-05-24 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| JPWO2016104630A1 (ja) | 2014-12-26 | 2017-10-05 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP6634070B2 (ja) | 2015-03-27 | 2020-01-22 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| WO2018071343A1 (en) * | 2016-10-10 | 2018-04-19 | Dong-A Socio Holdings Co., Ltd. | Heteroaryl compounds and their use as mer inhibitors |
-
2019
- 2019-05-08 UA UAA202007104A patent/UA126099C2/uk unknown
- 2019-05-08 BR BR112020022790-0A patent/BR112020022790A2/pt active Search and Examination
- 2019-05-08 KR KR1020190053818A patent/KR102325422B1/ko active IP Right Grant
- 2019-05-08 WO PCT/KR2019/005997 patent/WO2019216742A1/ko unknown
- 2019-05-08 JO JOP/2020/0282A patent/JOP20200282A1/ar unknown
- 2019-05-08 RU RU2020136431A patent/RU2768755C1/ru active
- 2019-05-08 JP JP2020562707A patent/JP7199774B2/ja active Active
- 2019-05-08 CN CN201980031203.8A patent/CN112105604B/zh active Active
- 2019-05-08 AU AU2019265268A patent/AU2019265268C1/en active Active
- 2019-05-08 EP EP19800582.9A patent/EP3778577B1/en active Active
- 2019-05-08 DK DK19800582.9T patent/DK3778577T3/da active
- 2019-05-08 PE PE2020001822A patent/PE20211496A1/es unknown
- 2019-05-08 MX MX2020011960A patent/MX2020011960A/es unknown
- 2019-05-08 US US17/054,084 patent/US11447480B2/en active Active
- 2019-05-08 SG SG11202011083PA patent/SG11202011083PA/en unknown
- 2019-05-08 CA CA3099268A patent/CA3099268C/en active Active
- 2019-05-08 IL IL278435A patent/IL278435B2/en unknown
-
2020
- 2020-11-06 CL CL2020002887A patent/CL2020002887A1/es unknown
- 2020-11-09 PH PH12020551900A patent/PH12020551900A1/en unknown
- 2020-11-12 CO CONC2020/0014186A patent/CO2020014186A2/es unknown
- 2020-11-20 ZA ZA2020/07260A patent/ZA202007260B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020014186A2 (es) | 2020-11-30 |
| KR102325422B1 (ko) | 2021-11-11 |
| AU2019265268A1 (en) | 2020-12-17 |
| CA3099268C (en) | 2023-03-07 |
| RU2768755C1 (ru) | 2022-03-24 |
| WO2019216742A1 (ko) | 2019-11-14 |
| IL278435B1 (en) | 2024-02-01 |
| JP7199774B2 (ja) | 2023-01-06 |
| PE20211496A1 (es) | 2021-08-11 |
| DK3778577T3 (da) | 2023-09-25 |
| EP3778577A1 (en) | 2021-02-17 |
| IL278435A (es) | 2021-03-01 |
| CL2020002887A1 (es) | 2021-05-14 |
| KR20190129009A (ko) | 2019-11-19 |
| ZA202007260B (en) | 2022-07-27 |
| US11447480B2 (en) | 2022-09-20 |
| UA126099C2 (uk) | 2022-08-10 |
| CN112105604A (zh) | 2020-12-18 |
| AU2019265268C1 (en) | 2022-08-04 |
| BR112020022790A2 (pt) | 2021-02-02 |
| PH12020551900A1 (en) | 2021-05-31 |
| EP3778577A4 (en) | 2021-03-31 |
| AU2019265268B2 (en) | 2022-04-28 |
| JOP20200282A1 (ar) | 2020-11-08 |
| JP2021521260A (ja) | 2021-08-26 |
| CN112105604B (zh) | 2024-01-09 |
| CA3099268A1 (en) | 2019-11-14 |
| SG11202011083PA (en) | 2020-12-30 |
| IL278435B2 (en) | 2024-06-01 |
| US20210284634A1 (en) | 2021-09-16 |
| EP3778577B1 (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020008271A (es) | Inhibidor de fap. | |
| MX2018005193A (es) | Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. | |
| EA201790124A1 (ru) | Соли берберина, соли урсодезоксихолевой кислоты и их комбинации, способы получения и применения | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| PH12018501988A1 (en) | Agent for increasing intestinal butyric acid and proliferation agent for butyric acid-producing bacteria | |
| NZ591326A (en) | An extended release pharmaceutical composition of entacapone or salts thereof | |
| MX2007000304A (es) | Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos. | |
| JP2015522573A5 (es) | ||
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| CA2565993A1 (en) | Salt of 4-or 5- aminosalicylic acid | |
| WO2018169282A3 (ko) | Atpif1을 함유하는 당뇨 치료용 약학조성물 | |
| MX2016008102A (es) | Composiciones y métodos para tratar la acumulacion de tejido graso. | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| WO2007081486A3 (en) | Oral administration of defensins to treat intestinal diseases | |
| WO2011087835A3 (en) | Novel compositions and methods for treating inflammatory bowel disease and airway inflammation | |
| WO2008008882A3 (en) | Glucocorticoid receptor modulator and methods of use | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| WO2020009740A3 (en) | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders | |
| WO2009038090A1 (ja) | セサミン類とアラキドン酸類を含有する組成物 | |
| MX2017009325A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| WO2007121545A8 (en) | S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions | |
| PH12020551900A1 (en) | Novel compound exhibiting enteropeptidase inhibitory activity | |
| EA201290485A1 (ru) | Производные бензамида |